Needham & Company Reiterates NextCure (NXTC) at Buy, Focus Remains on Upcoming Results of Yale Study
Tweet Send to a Friend
Needham & Company analyst Chad Messer reiterated a Buy rating and $14.00 price target on NextCure Inc. (NASDAQ: NXTC), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
